Literature DB >> 24158007

Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease.

Nasser Samir El-Okdi1, Daniel Lumbrezer, Djuro Karanovic, Abhimanyu Ghose, Ragheb Assaly.   

Abstract

Serotonin syndrome (SS) is a life-threatening adverse reaction that can result from the therapeutic use of serotonergic drugs or accidental drug interactions. Tramadol is a drug that is widely prescribed because of its low abuse potential, but physicians need to be aware of its significant potential to cause SS because it inhibits serotonin reuptake. Ziprasidone is an atypical antipsychotic that can also cause dangerous interactions to cause SS because it is not only a potent 5-HT1A agonist but also has been reported to inhibit serotonin reuptake with an affinity similar to tricyclic antidepressants, in addition to inhibiting reuptake of norepinephrine. We are describing the clinical characteristics of a gentleman with bipolar disorder and Parkinson disease who presented with SS, despite having a deep brain stimulator in the subthalamic nucleus, which decreases central serotonin levels, and a discussion of the factors that contributed to his presentation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24158007     DOI: 10.1097/MJT.0b013e3182456d88

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  3 in total

1.  A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson's Disease.

Authors:  John R Younce; Albert A Davis; Kevin J Black
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

2.  Assessment and management of serotonin syndrome in a simulated patient study of Australian community pharmacies.

Authors:  Brett Macfarlane; Jenny Bergin; Gregory M Peterson
Journal:  Pharm Pract (Granada)       Date:  2016-06-15

3.  Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease.

Authors:  Christopher C Yang; Mengnan Zhao
Journal:  J Med Internet Res       Date:  2018-10-11       Impact factor: 5.428

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.